1Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, et al. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist, 2006,11 (6) :612 -23.
2Citri A, Yarden Y. EGF-ERBB signalling: towards the systems leval. Nat Rev Mol Cell Biol. 2006,7(7) :505 -16.
3Baselga J, Arteaga C L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Clin Oncol,2005, 23(11) :2445 -59.
5Vivanco I, Sawyers C L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer,2002,2(7) :489 -501.
6Capdevila J, Elez E, Macarulla T, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev, 2009,35 (4) :354 - 63.
7Ueda S, 0gata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas,2004,29( 1 ) :e1 - 8.
8Roch F, Jimenez G, Casanova J. EGFR signalling inhibits Capicua - dependent repression during specification of Drosophila wing veins. Development ,2002,129(4) :993 - 1002.
9Sasaki T, Kitadai Y, Nakamum T, et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia,2007,9(12) :1066 -77.
10Arteaga C L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Clin Oncol, 2001,19:32s -40s.
二级参考文献6
1Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas ,2004,29 : e1-e8.
2Bloomston M, Bhardwaj A, Ellison EC, et al. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg,2006,23:74-79.
3De Jager J,Stebbing J. Erlotinib or capecitabine with gemcitabine in pancreatic cancer. Future Oncol,2006,2:161-163.
4Herbst RS. Erlotinib ( Tarceva ) : an update on the clinical trial program. Semin Oncol,2003 ,30 :34-46.
5Durkin AJ, Bloomston PM, Rosemurgy AS,et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg,2003 ,186 :431-436.
6Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol, 2005,23 : 2445 -2459.
